RASHMIVU LLC

Columbus, OH · Biotech · Private

Stem cell-based regenerative therapy using human corneal endothelial stem cells (hCESCs) delivered via intracameral injection or sheet grafting for corneal endothelial repair

Grants
$642K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Corneal Endothelial Stem Cells for Treatment of Corneal Endothelial Dystrophies$41,519
Federal grantDepartment of Health and Human Services · Phase II · Regenerative Therapy for Corneal Endothelial Dystrophies and Injuries$300,000
Federal grantDepartment of Health and Human Services · Phase I · Regenerative Therapy for Corneal Endothelial Dystrophies and Injuries$300,000
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2036Endomet Biosciences, Inc.——
2037Apeximmune Therapeutics Inc.——
2038VXBIOSCIENCES, INC.——
2039RASHMIVU LLC——
2040Cell X Technologies, Inc.——
2041UP ONCOLYTICS, INC.——
2042JPT America, Inc.—$600K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.